KRAS and pancreatic neoplasm: However, KRAS-mutated pancreatic cancer cell lines (PANC-1 and MIA PaCa-2) and KRAS-transformed fibroblast cells with elevated ROS levels (NIH3T3/KRAS)28 were less sensitive to our MTH1 inhibitors (Supplementary Fig. S2).